CLINUVEL’s mission is to translate its accumulated technology and expertise on the melanocortin family of hormones to wider audiences with unmet needs through the development of solutions for conditions of skin and brain.
Financial performance
Strong performance continued: Eighth consecutive annual profit with growth in revenues and cash reserves
Operating & Financial Review
“When we build, let us think that we build forever.”
John Ruskin
Letter from the chair
Looking to the future, we are actively executing our vision of a strategic house of melanocortins...
Letter from the MD
“we are at the cusp of realising a future of new delivery methods and translating peptide technologies in both a host of untreated diseases and consumer healthcare.”